Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAR001 in metabolic dysfunction with hypertriglyceridemia
NCT05896254Phase 2Completed
- Sponsor
- Marea Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MAR001 in hypertriglyceridemia, sponsored by Marea Therapeutics. Started Jul 2023; status: completed.
02
Drugs
MAR001
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05896254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896254.